Effect of intensive granulocyte and monocyte adsorptive apheresis in patients with ulcerative colitis positive for cytomegalovirus. by Fukuchi, Takumi et al.
Title
Effect of intensive granulocyte and monocyte adsorptive
apheresis in patients with ulcerative colitis positive for
cytomegalovirus.
Author(s)
Fukuchi, Takumi; Nakase, Hiroshi; Matsuura, Minoru;
Yoshino, Takuya; Toyonaga, Takahiko; Ohmori, Katsuyuki;
Ubukata, Satoshi; Ueda, Aya; Eguchi, Takaaki; Yamashita,
Hiroshi; Ito, Dai; Ashida, Kiyoshi
CitationJ urnal of Crohn's & colitis (2013), 7(10): 803-811
Issue Date2013-11-01
URL http://hdl.handle.net/2433/179280




Fukuchi, et al. 
Effect of Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients 
with Ulcerative Colitis Positive for Cytomegalovirus  
Running title: Intensive GMAA for active UC with CMV 
 
Takumi Fukuchi a, Hiroshi Nakase b, Minoru Matsuura b, Takuya Yoshino b,  
Takahiko Toyonaga b, Katsuyuki Ohmori c, Satoshi Ubukata a, Aya Ueda a, 
Takaaki Eguchi a, Hiroshi Yamashita a, Dai Ito a, Kiyoshi Ashida a 
 
a Department of Gastroenterology and Hepatology, Osakafu Saiseikai Nakatsu Hospital, 
Osaka, Japan 
b Department of Gastroenterology and Hepatology, Graduate School of Medicine, 
Kyoto University Hospital, Kyoto, Japan 
c Department of Clinical Laboratory, Graduate School of Medicine, Kyoto University 
Hospital, Kyoto, Japan 
 
Correspondence to: Hiroshi Nakase MD, PhD, Lecturer, Department of 
Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto university 
Hospital, Kyoto, Japan 
54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan 
Phone: +81 75 751 4319, Fax: +81 75 751 4303 
E-mail: hiropy_n@kuhp.kyoto-u.ac.jp 
 
T.Fukuchi takuleotakuleo@yahoo.co.jp H.Nakase hiropy_n@kuhp.kyoto-u.ac.jp 
M. Matsuura minomats@kuhp.kyoto-u.ac.jp  T. Yoshino takuyayoshino@gmail.com 
1 
Fukuchi, et al. 
T. Toyonaga toyo.necco@gmail.com  K. Ohmori ohmori@kuhp.kyoto-u.ac.jp 
S.Ubukata fgdnq486@yahoo.co.jp  A. Ueda ejieji@hotmail.co.jp  
T.Eguchi egugu0515@yahoo.co.jp H.Yamashita onakaryoko@gmail.com 
D.Ito daiito0423@yahoo.co.jp  K.Ashida 25001@nakatsu.saiseikai.or.jp 
 
[Key words] ulcerative colitis, granulocyte and monocyte adsorptive apheresis, 
cytomegalovirus  
2 
Fukuchi, et al. 
Abstract  
Background and aim: Cytomegalovirus (CMV) exacerbates ulcerative colitis (UC) 
refractory to immunosuppressive therapies. The conditions under which CMV 
reactivation occurs in patients with UC, however, is unclear. In addition, the diagnostic 
and treatment strategies for UC positive for CMV have not been established. 
Granulocyte and monocyte adsorptive apheresis (GMAA) is natural biological therapy 
for UC in which the granulocytes/macrophages producing inflammatory cytokines are 
removed. We investigated the rate of colonic CMV reactivation and the efficacy of 
GMAA in active UC patients positive for CMV without concomitant corticosteroid 
(CS) therapy. 
Methods: Fifty-one active UC patients without concomitant CS therapy were enrolled. 
Colonic CMV reactivation was examined by real-time polymerase chain reaction (PCR) 
using biopsy specimen and/or histological examination. All patients were treated with 
intensive GMAA (twice per week). Rates of clinical remission and mucosal healing 
were compared between UC patients positive and negative for CMV.  
Results: Of 51 patients, 15 (29.4%) were diagnosed as CMV positive. The clinical 
remission rates following intensive GMAA did not differ between UC patients positive 
and negative for CMV (73.3% vs 69.4%, p = 0.781). Proportion of patients achieving 
mucosal healing was also similar between these two groups. CMV-DNA became 
negative in all UC patients positive for CMV who achieved clinical remission 1 week 
after completion of intensive GMAA.  
Conclusions: Intestinal inflammation might trigger CMV reactivation in a 
subpopulation of active UC patients without CS treatment. GMAA could be a promising 
option for active UC positive for CMV.  
3 
Fukuchi, et al. 
[Key words] ulcerative colitis, granulocyte and monocyte adsorptive apheresis, 
cytomegalovirus 
4 
Fukuchi, et al. 
1. Introduction 
Cytomegalovirus (CMV) is a double-stranded DNA virus and a member of the human 
herpesvirus family.1 CMV infection is a common viral infection in humans, occurring in 
approximately 50% to 80% of adults, depending on the population studied.2-4 Once the 
infection is acquired, CMV infection persists in a latent state, similar to other herpes 
virus infections.4-7 Viral replication of CMV, however, can be reactivated under 
conditions of immunosuppression, such as organ transplantation and 
immunosuppressive treatment.4-6 The pathogenicity of CMV in a flare-up of ulcerative 
colitis (UC) remains unclear, but colonic CMV reactivation is considered to be an 
exacerbating factor in patients with UC patients refractory to immunosuppressive 
therapies because of the poor prognosis of UC patients with concomitant CMV 
infection.4,8-12 Furthermore, in addition to immunosuppressive treatment, the disease 
activity itself can predispose patients with UC to reactivation of latent CMV in the 
colonic tissues.8,9 Therefore, it is very important to establish optimal modalities of 
diagnosing colonic CMV reactivation. 
Among the various modalities used to diagnose CMV infection, histological 
examination, including inclusion body and immunohistochemistry (IHC) for CMV, 
together with virological analysis using peripheral blood samples, such as serology, 
blood CMV viral load determined by antigenemia, and quantitative real-time 
polymerase chain reaction (PCR), have been mainstays of the diagnosis. In contrast, 
real-time PCR assay using colonic tissues samples (tissue PCR) is recommended by the 
European Crohn’s and Colitis Organization guidelines as an alternative to IHC for 
CMV to investigate the presence of colonic CMV reactivation in immunomodulatory 
refractory cases of inflammatory bowel disease (IBD), because the CMV-DNA load can 
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be high in colonic tissue even when IHC and other modalities using peripheral blood 
samples for CMV infection are all negative.4 Yoshino et al. reported the usefulness of 
quantitative real-time PCR assays using colonic biopsy specimens for early detection of 
colonic CMV reactivation in patients with refractory UC, and demonstrated that colonic 
CMV reactivation occurred mainly in inflamed colonic mucosa.13 Furthermore, Roblin 
et al. recently reported that CMV-DNA was detected in inflamed intestinal tissues 
whereas no trace of the CMV-DNA was detected in the endoscopically normal colonic 
tissue.14 Of note, the patients enrolled in their study were all naïve to intravenous 
corticosteroids or cyclosporine treatment, which generally lead to colonic CMV 
reactivation with histological lesions. These data suggest that colonic CMV reactivation 
in inflamed tissue might easily occur in a subpopulation of active UC patients without 
immunosuppressive treatment, depending on their immune condition. Therefore, it is 
clinically important to check the CMV-DNA load in colonic tissue for monitoring CMV 
infection and selecting anti-inflammatory therapy without stimulating CMV 
reactivation. 
Granulocyte and monocyte adsorptive apheresis (GMAA) is an extracorporeal therapy 
performed with the Adacolumn (JIMRO, Gunma, Japan), which selectively depletes 
granulocytes and monocytes from the peripheral blood.15-17 Several previous studies 
reported achieving a high remission rate in patients with active UC following GMAA 
therapy, and Sakuraba’s group and our data suggest that intensive GMAA (twice per 
week) induces higher clinical and endoscopic remission compared with weekly 
GMAA.18, 19 In addition, our recent data and previous case series revealed that GMAA 
could be a suitable therapeutic option for patients with active UC prior to starting 
corticosteroid (CS) therapy because of a striking difference in the clinical response to 
6 
Fukuchi, et al. 
GMAA between steroid-naïve and steroid-dependent patients.19-21 Furthermore, it was 
recently reported that GMAA could be safe for UC patients with a history of CMV 
infection due to the avoidance of colonic CMV reactivation compared with UC patients 
treated with immunosuppressive drugs.22 Theoretically, GMAA removes granulocytes 
and monocytes/macrophages, where CMV infection is latent and reactivates. GMAA 
does not affect colonic CMV reactivation. These findings together suggest that intensive 
GMAA might be optimal therapy for the induction of remission in UC patients with 
colonic CMV reactivation. 
In the present study, we investigated (1) The rate of CMV infection in UC patients not 
receiving corticosteroids by using tissue PCR, and (2) compared the efficacy and safety 
of intensive GMAA between UC patients with CMV infection and UC patients without 
CMV infection. 
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2. Materials and Methods 
2.1. Patients 
From January 2010 to July 2011, a total of 51 patients with moderate to severe active 
UC were enrolled in this study. The diagnosis of UC was based on clinical, endoscopic, 
radiological, and histological findings. Fecal bacterial culture yielded no specific 
pathogens in any of the patients. Patients with UC who were older than 17 years were 
consecutively recruited if they had newly or relapsing active disease. None of the 
patients had received corticosteroid treatment. Moderate to severe active UC was 
defined as a Clinical Activity Index (CAI)23 higher than 7.  
 
2.2. Assessment of endoscopic severity 
Endoscopic severity of UC was assessed using the Mayo Endoscopic Score24 
(Mayo-ES) as follows: normal or inactive disease = score 0; erythema, decrease of 
vascular pattern and mild friability as mild disease = score 1; marked erythema, lack of 
vascular pattern, friability, erosions as moderate disease = score 2; spontaneous 
bleeding and ulceration as severe disease = score 3.  
 
2.3. CMV antigenemia 
The antigenemia assay was performed using a monoclonal antibody against a CMV 
structural protein of the 65 kDa lower-matrix phosphoprotein (C7HRP or C10C11).  
 
2.4. Histopathological examination 
Colonic biopsy specimens were obtained from inflamed colonic mucosa, fixed in 
formalin, embedded in paraffin, and stained with hematoxylin and eosin (H&E), and 
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IHC was performed using anti-CMV monoclonal antibodies (clones:DDG9/CCH2, 
DAKO, Tokyo, Japan).25,26 The results positive for CMV in IHC were further 
categorized as typical if the CMV IHC-positive cells had nuclear enlargement, and 
negative if CMV-positive IHC staining was not seen. 26 
 
2.5. Quantitative real-time PCR in inflamed colonic mucosa (mucosal-PCR) 
DNA for the real-time PCR assay was extracted from inflamed colonic mucosa obtained 
at endoscopic examination using a QIAamp DNA Blood Mini Kit (Qiagen, Tokyo, 
Japan) according to the manufacturer’s instructions. The assay was performed using an 
ABI Prism 7700 Sequence Detector System (PerkinElmer Applied Biosystems, San 
Jose, CA) as described previously.7 Oligonucelotide primers specific for the immediate 
early gene were used for CMV-DNA amplification. The sequence of the upstream 
primer was 5’-GACTAGTGTGATGCTGGCCAAG-3’, and that of the downstream 
primer was 5’-GCTACAATAGCCTCTTCCTCATCTG-3’. The 
6-carboxyfluorescein-labeled probe was 
5’-AGCCTGAGGTTATCAGTGTAATGAAGCGCC-3’. The PCR conditions were as 
follows: incubation at 95℃ for 10 min, 50 cycles of 95℃ for 15 s, followed by 
incubation at 62℃ for 1 min. Cases in which the CMV-DNA copy number was over 10 
copies/µg DNA were defined as positive for CMV infection.12,22 
 
2.6. Diagnosis of colonic CMV reactivation  
Cases in which CMV was detected by at least one of the two methods above 
(histological examination with immunohistochemistry and/or quantitative real-time 
PCR) were diagnosed as positive for colonic CMV reactivation.  
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2.7. Treatment 
Intensive GMAA treatments were performed as previously described with no CS 
therapy and no antiviral therapy, irrespective of whether the patients were CMV 
positive or negative.18,19 The maximum number of GMAA sessions allowed was 10 (Fig 
1). Blood access was obtained through the antecubital vein in one arm, and the return to 
the patient was through the antecubital vein in the contralateral arm, both through a 
19-gauge needle. GMAA was performed at a flow rate of 30 mL/min for 60 min, with 
the aim to expose 1800 mL blood/session (one session). None of the UC patients 
positive for CMV received antiviral therapy, and adverse events were recorded at each 
visit during intensive GMAA. 
 
2.8. Assessment  
We investigated the detection rate of colonic CMV reactivation in patients with 
moderate to severe UC and without CS. Next, we examined the clinical factors related 
to colonic CMV reactivation by comparing several clinical parameters between 
CMV-positive and CMV-negative UC patients. Moreover, we evaluated the efficacy of 
intensive GMAA between those patients. The primary efficacy of intensive GMAA was 
evaluated based on the clinical remission rate at weeks 2, 4, and 6. Clinical remission 
was defined as CAI ≤ 4. Secondary efficacy was evaluated based on the Mayo-ES. We 
compared the Mayo-ES between CMV-positive and CMV-negative UC patients at 1 
week after the completion of intensive GMAA. The proportion of patients with mucosal 
healing 1 week after the completion of intensive GMAA was determined. Mucosal 
healing was defined as Mayo-ES of 0 or 1, in accordance with the report of Rutgeets et 
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al. and our group.19,27  
 
2.9. Statistical analysis 
Data are presented as mean ± SE. Categorical and continuous data were compared using 
a two-tailed Fisher exact test and Student’s t-test. A p value of less than 0.05 was 
considered statistically significant. 
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3. Results 
3.1. Clinical characteristics 
The clinical characteristics of 51 UC patients without CS therapy are summarized in 
Table 1. Mean patient age was 38.2 ± 2.1 years old (range 17-62 years), and mean CAI 
was 10.4 ± 0.5. The extent of the disease was pancolitis (13.7%) and left-sided colitis 
(86.3%). The mean Mayo-ES was 2.29 ± 0.06. Of the 51 patients, 29 patients (56.9%) 
had been treated with 5-aminosalicylate acid (5-ASA) and 14 patients (27.5%) had been 
treated with azathioprine (AZA)/6-mercaptoprine (6MP) (Table 1). 
 
3.2. Detection rate of CMV infection in active UC patients without CS therapy 
Of the 51 patients, 15 (29.4%) were diagnosed as positive for colonic CMV reactivation 
(Table 2). CMV-DNA was detected in the inflamed colonic mucosa of all 15 patients, 
and histological examination was positive in three (6.7%) of these UC patients. Patients 
negative for CMV-DNA in the colonic mucosa were negative for both CMV 
antigenemia and histologic examination.  
 
3.3. Differences in the clinical parameters between UC patients without CS therapy 
positive or negative for CMV 
We compared differences in the age, sex, disease location, CAI, and Mayo-ES between 
CMV-positive and CMV-negative UC patients. Other than disease duration, these 
clinical parameters did not differ between groups (Table 3). Importantly, the positive 
rate of CMV-DNA was significantly lower in UC patients treated with AZA/6MP than 
in those without (Table 3). 
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3.4. Clinical efficacy of intensive GMAA treatment 
Two weeks after starting intensive GMAA, 53.3% of UC patients that were CMV 
positive went into clinical remission compared with 52.7% of those who were CMV 
negative. At 6 weeks, 73.3% of the UC patients positive for CMV receiving intensive 
GMAA had a clinical remission in comparison with 69.4% of those negative for CMV 
(p = 0.781). There was no significant difference in the clinical remission rate following 
treatment with intensive GMAA between UC patients that were CMV positive and 
those that were CMV negative (Fig 1). Mean time to clinical remission was 17.8 ± 2.0 
days in UC patients that were CMV positive and 20.0 ± 1.8 days for those that were 
CMV negative (p = 0.496). Mean number of GMAA sessions to clinical remission was 
5.1 ± 0.6 sessions in UC patients that were CMV positive and 5.7 ± 0.4 sessions for 
those that were CMV negative (p = 0.420). One patient transiently complained of 
headache and nausea. No other serious side effects were observed throughout intensive 
GMAA treatment. 
 
3.5. Mucosal healing induced by intensive GMAA treatment 
We investigated the association between the efficacy of intensive GMAA on mucosal 
healing and CMV infection in patients with UC. Upon initiating intensive GMAA, the 
Mayo-ES was 2.2 ± 0.1 in patients with UC that were CMV-positive and 2.3 ± 0.1 in 
those that were CMV-negative (p = 0.786; Table 3). At 1 week after the completion of 
intensive GMAA, the Mayo-ES was 1.1 ± 0.3 in UC patients that were CMV-positive 
and 1.0 ± 0.2 in those that were CMV-negative (p = 0.829; Fig 2A). There was no 
significant difference in the proportion of patients who achieved mucosal healing by 
intensive GMAA between patients with UC that were positive or negative for CMV 
13 
Fukuchi, et al. 
(66.7% vs. 69.4%, p = 0.846; Fig 2B). 
 
3.6. Disappearance of CMV infection after intensive GMAA treatment in UC 
patients positive for CMV 
To evaluate the effect of intensive GMAA on CMV infection in patients with UC, we 
compared the CMV-DNA load before and after intensive GMAA. At 1 week after the 
completion of intensive GMAA, 11 of 15 patients positive for CMV (73.3%) became 
negative for CMV (Table 4). In addition, all of these 11 patients achieved clinical 
remission only 1 week after the completion of intensive GMAA. Moreover, 10 of 11 
patients (90.9%) simultaneously achieved mucosal healing (Table 4; Case1-11). On the 
other hand, four patients who were still positive for CMV at 1 week after the 
completion of intensive GMAA did not achieve clinical remission (Table 4; Cases 
12-15).  
Moreover, we observed the clinical outcome of patients with positive IHC in 
comparison with those with negative IHC. Two of 3 UC patients (66.7%) with 
CMV-DNA (+)/ IHC (+), who achieved clinical remission and mucosal healing, become 
negative for both CMV-DNA and IHC after GMAA (Table 4; Cases 1, 2), while the 
remaining one, who could not achieve clinical remission and mucosal healing, was still 
positive for both CMV-DNA and IHC (Table 4; Cases 12). On the other hands, 9 of 12 
patients (75%) with CMV-DNA (+)/IHC (-) achieved clinical remission after GMAA 
and 8 of those (66.7%) achieved mucosal healing (Table 4; Cases 3-10, 13-15). In this 
study, we could not observe any difference of the effect of GMAA between the UC 
patients with CMV-DNA (+)/IHC (+) and those with CMV-DNA (+)/IHC (-). 
 
14 
Fukuchi, et al. 
3.7. The factors associated to CMV persistence or clearance by intensive GMAA in 
patients with UC positive for CMV before treatment 
We compared as age, sex, disease duration, disease location, previous treatment, copy 
numbers of mucosal-PCR, IHC positive rate, CAI and Mayo-ES between UC patients 
positive for CMV before treatment CMV persistence and clearance at 1 week after the 
completion of intensive GMAA. However, possible clinical factors associated with 
CMV persistence were not identified in this study (Table 5).  
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4. Discussion 
The findings of the present study revealed that colonic CMV reactivation occurred in 
the inflamed colonic mucosa of patients with active UC that were not receiving CS 
therapy. Intensive GMAA was safe and effective for inducing rapid clinical remission in 
UC patients positive for CMV, resulting in the disappearance of CMV-DNA in their 
colonic mucosa. Further, our findings suggested that intestinal inflammation of UC 
could trigger the colonic CMV reactivation whether or not immunosuppressive 
therapies were used, and that GMAA is a promising therapy for UC with concomitant 
CMV infection and does not reactivate CMV.  
CMV infection is a well-known complication in immunosuppressed patients, such as 
after bone marrow transplantation and HIV infection.5,6 CMV is associated with steroid 
refractoriness in IBD.8,9 The role of CMV in the induction of inflammation and its 
relationship with immunosuppressive therapies is not clear, however, because the 
virological criteria for diagnosing CMV infection are not standardized.  
Detection of the antigen (pp65 antigenemia assay) or CMV-DNA by PCR in the blood, 
which can quantify the viral load and is generally applied for the diagnosis of CMV 
infection, are not necessary useful for diagnosing CMV-induced colitis because 
gastrointestinal disease related to CMV infection can occur even when CMV is not 
detected in the blood. The detection of CMV in biopsy specimens by histological 
examination, such as the detection of inclusion bodies and IHC, has been the golden 
standard for diagnosis of the involvement of CMV in gastrointestinal diseases.28 It is 
important to note, however, that histological markers of CMV disease in the colonic 
tissue can be negative even if the CMV-DNA load is high at the tissue level. Yoshino et 
al. reported the usefulness of a mucosal PCR method for detecting colonic CMV 
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reactivation in patients with UC.13 Recently, Roblin et al. reported the importance of 
determining the CMV-DNA load by PCR because this quantitative detection of 
CMV-DNA in the intestinal tissue could predict resistance to steroid treatment in 
patients with UC.14 The European Crohn’s and Colitis Organization guidelines 
recommended the use of tissue PCR as an alternative to IHC for investigating colonic 
CMV reactivation in immunomodulatory-refractory cases of IBD.4 Thus, in this regard, 
application of the mucosal PCR method for evaluating CMV infection in this study is 
considered reasonable.  
The present study showed that the 29.4% of UC patients not receiving CS were CMV 
positive. Our data are consistent with the findings of both Roblin and Domènech that 
mucosal inflammation in UC, rather than immunosuppressive therapy such as with CS, 
contributes to the colonic CMV reactivation in intestinal tissue.14,29 An interesting 
finding was that the positive rate of CMV-DNA was significantly lower in UC patients 
treated with AZA/6MP than in those without. In vitro data showing the proliferation of 
CMV in fibroblasts inhibited by AZA/6MP support our clinical observation.30 On the 
other hand, Yoshino et al. reported that the 56.7% of patients with UC refractory to 
immunosuppressive therapies were CMV-positive.13 Based on our data and previous 
reports, whether or not UC patients exhibit CMV-DNA in the inflamed mucosa might 
depend on both patient’s immune condition and subsequent immunosuppressive 
therapy.  
Several studies have reported conflicting data regarding the endoscopic findings in UC 
patients with colonic CMV reactivation. Suzuki et al. reported a correlation between the 
presence of irregular punched-out and longitudinal ulcerations with colonic CMV 
reactivation.31 Yoshino et al., however, demonstrated that the endoscopic findings did 
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not differ between UC patients under immunosuppressive therapies that were positive or 
negative for CMV-DNA.13 Roblin et al. reported the lack of a correlation between 
CMV-DNA tissue load and endoscopic findings.14 In the present study, we observed no 
significant difference in the endoscopic score between UC patients without CS 
treatment that were positive or negative for CMV-DNA. Although these data suggest 
that the use of different criteria to define colonic CMV reactivation leads to different 
results, clearly distinguishing between UC patients that are CMV positive and those that 
are CMV negative by endoscopic findings alone is difficult.  
There is no standardized therapeutic regimen for UC patients with concomitant CMV 
infection. Although there are several reports of the effect of antiviral treatments on UC 
patients with colonic CMV reactivation refractory to CS therapy,10-12,14,29,32 a precise 
method of identifying patients whose disease improves with antiviral therapy has not 
yet been established. Thus, it remains unclear how and when to start antiviral treatment 
for UC patients with concomitant CMV infection. Roblin et al. revealed striking data 
indicating that UC patients with a tissue CMV-DNA load above 250 copies/mg required 
early antiviral treatment.14 Their data demonstrated the importance of evaluating the 
tissue CMV-DNA load in UC patients to identify those positive for tissue CMV-DNA 
who should be treated with antiviral treatment. Their data suggested that a higher level 
of CMV-DNA in the colonic mucosa could affect the efficacy of immunomodulatory 
treatments, and antiviral treatment might be required to prevent further colonic CMV 
reactivation during immunosuppressive treatment for patients with a high CMV-DNA 
load. In this regard, the best way to treat UC patients with concomitant CMV infection 
might be to reduce colonic inflammation without inducing colonic CMV reactivation.  
It is well established that the CMV-specific cluster of differentiation (CD) 4+ T-cells, 
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CD 8+ T-cells, and γδ T-cells is important for controlling and restricting viral replication 
in hosts with CMV persistent infection.5,6 The production of tumor necrosis factor 
(TNF)- α is strongly associated with colonic CMV reactivation.5 The GMAA system 
used in this study is a natural biological therapy for selectively removing 
granulocytes/macrophages from the peripheral blood that reduces the production of 
inflammatory cytokines such as TNF- α, interleukin (IL)-6, and IL-8, without reducing 
lymphocytes. Moreover, the number of CD14+ monocytes producing TNF- α is reduced 
from the peripheral blood by GMAA.33-35 These anti-inflammatory mechanisms of 
GMAA might comprise a promising treatment for UC patients with concomitant CMV 
infection. In fact, Yoshino et al. reported that GMAA did not induce colonic CMV 
reactivation in UC patients with a history of CMV infection.22 In the present study, the 
clinical remission rate and mucosal healing following intensive GMAA did not differ 
significantly between UC patients positive for CMV and UC patients negative for CMV. 
A similar tendency was observed for the mucosal healing ratio. Notably, CMV-DNA in 
the colonic mucosa became negative in all UC patients positive for CMV that achieved 
clinical remission after intensive GMAA. These data strongly suggest that GMAA 
could be an optimal therapeutic strategy for patients with active UC that are 
CMV-positive.  
In conclusion, our mucosal PCR data demonstrated that 29.4% of patients with active 
UC prior to the administration of CS were positive for CMV. This finding indicates that 
local intestinal inflammation can trigger colonic CMV reactivation in a subpopulation 
of patients with active UC. Additional immunosuppressive therapies, including CS, 
might also induce colonic CMV reactivation in these patients, yielding refractory UC. 
Moreover, our present data showed that intensive GMAA therapy was promising for 
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UC patient positive for CMV because 73.3% of these patients achieved clinical 
remission with disappearance of CMV after completion of intensive GMAA. These data 
strongly suggest that GMAA therapy could reduce colonic inflammation without 
affecting CMV reactivation. However, additional clinical trials should be required to 
confirm the efficacy of GMAA in UC patients positive for CMV.
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Figure Legends 
Figure 1 
The clinical remission rate following intensive GMAA. There was no significant 
difference in the clinical remission rate following intensive GMAA treatment between 
UC patients positive for cytomegalovirus (CMV) and UC patients negative for CMV. 
 
Figure 2  
Mayo Endoscopic Score and mucosal healing rate at 1 week after the completion of 
intensive GMAA treatment. The Mayo Endoscopic Score was not significantly different 
at 1 week after completing the intensive GMAA treatment between UC patients that 
were CMV-positive and those that were CMV-negative (A). The mucosal healing rate 
was not significantly different at 1 week after completing the intensive GMAA 
treatment between UC patients that were CMV-positive and those that were 
CMV-negative (B). 
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Table 1.  Clinical characteristics of 51 patients with active UC 
without corticosteroids. 
Age (years) 38.2 ± 2.2 
Sex (male/female) 27/24  
Disease duration (months) 53.3 ± 10.8 
Disease location  
 Left-sided 44 (86.3) 
 Pancolitis 7 (13.7) 
Clinical Activity Index 10.4 ± 0.5 
Mayo Endoscopic Score 2.3 ± 0.1 
Previous treatment   
5-ASA              No. Patients  29 (56.9) 
 Dose (mg/day) 1549.0 ± 201.6 
AZA/6MP No. Patients  14 (27.5) 
  Dose (mg/day) 10.4 ± 2.7 
Number of patients is shown for sex, disease location, and previous 
treatment with 5-ASA and AZA/6-MP. Data are presented as mean 
± SE for age, disease duration, Clinical Activity Index, Mayo 
Endoscopic Score, and dose of 5-ASA and AZA/6MP.5-ASA, 
5-aminosalicylate acid; AZA, azathioprine; 6MP, 
6-mercaptopurine. Values in parentheses are percentages of all 51 




Fukuchi, et al. 
 
Table 2.  Detection rate of cytomegalovirus (CMV) infection in patients with active UC without corticosteroids. 
CMV infection No. patients 
CMV-DNA 




Positive 15 15 (100%) 0 3 (20.0%) 0 1 (6.7%) 
Negative 36 0 (%) 0 0 0 0 
Total 51 15 (29.4%) 0 3 (5.9%) 0 1 (2.0%) 
Number of patients is shown. IHC, immunohistochemistry; H&E, hematoxylin and eosin . Values in parenthesis on horizontal line of CMV 
positive are percentages of all 15 patients with UC positive for CMV. Values in parenthesis on horizontal line of CMV negative are 
percentages of all 36 patients with UC negative for CMV. Values in parenthesis on horizontal line of total are percentages of all 51 patients 
with UC.  
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Table 3. Comparison of clinical parameters of patients with active UC positive for CMV treated by intensive 
granulocyte and monocyte adsorptive apheresis (GMAA) with no corticosteroids between those 
disappearance or staying appearance for CMV at the end of GMAA 
  
CMV positive         
(n=15) 
CMV negative       
(n=36) 
p-value 
Age (years) 42.9 ± 3.8 36.2 ± 2.4 0.14 
Sex (male/female)  7/8 20/16 0.562 
Disease duration (months)  18.7 ± 7.1 67.8 ± 14.4 0.037 
Disease location 
   
 
Left-sided 13 (86.7) 31 (86.1) 0.958 
 
Pancolitis 2 (13.3) 5 (13.9) 
 
Previous treatment  
   
5-ASA              No. Patients 6 (40.0) 23 (63.9) 0.117 
 
Dose (mg/day) 1233.3 ± 421.5 1680.6 ± 225.7 0.317 
AZA/6-MP No. Patients 1 (6.7) 13 (36.1) 0.032 
 
Dose (mg/day) 1.7 ± 1.7 14.0 ± 3.6 0.037 
Clinical Activity Index 10.3 ± 0.8 10.4 ± 0.6 0.959 
Mayo Endoscopic Score 2.2 ± 0.1 2.3 ± 0.1 0.786 
Number of patients is shown for sex, disease location, and previous treatment. Data are presented as mean ± 
SE for age, disease duration, dose of 5-ASA and AZA/6-MP, Clinical Activity Index and Mayo Endoscopic 
Score. 5-ASA, 5-aminosalicylate; AZA, azathioprine; 6-MP, 6-mercaptopurine. Values in parenthesis on 
vertical line of CMV positive are percentages of all 15 patients with UC positive for CMV. Values in 
parentheses on vertical line of CMV negative are percentages of all 36 patients with UC negative for CMV. 
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Table 4.  Change in the Clinical Activity Index, Mayo Endoscopic Score, and CMV- DNA in inflamed mucosa in 15 patients 
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Case 15 16 11   2 3   3600 190   - -   
Mean 10.3 ± 0.8 3.4 ± 1.4   2.3 ± 0.1 1.1 ± 0.3   
7536.0 ±    
3457.8 
142.7 ±        
100.2 
        
Cases 1-11 were patients with UC who achieved clinical remission following intensive GMAA. Cases 12-15 were patients with 
UC who did not achieve clinical remission following intensive GMAA. Means are presented as mean ± SE for CAI,Mayo-ES, 
and CMV-DNA in inflamed mucosa. After GMAA; at 1 week after completion of intensive GMAA. CAI, Clinical Activity 
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Table 5. Comparison of clinical parameters of patients with active UC positive for CMV treated by intensive 
granulocyte and monocyte adsorptive apheresis (GMAA) with no corticosteroids between those 
disappearance or staying appearance for CMV. 
   
CMV disappearance  
(n=11) 
CMV appearance  
(n=4) 
Age (years) 45.4 ± 4.8 36.0 ± 4.9 
Sex (male/female)  5/6  2/2 




Left-sided 10 (90.9) 1 (9.1) 
 
Pancolitis 3 (75) 1 (25) 
Previous treatment  
  
5-ASA              No. Patients 4 (36.4) 2 (50) 
 
Dose (mg/day) 1750.0 ± 1030.8 1045.5 ± 458.3 
AZA/6-MP No. Patients 10 (90.9) 0 
 
Dose (mg/day) 2.3 ± 2.3 0 
CMV-DNA (copies / µg DNA）  9175.5 ± 4618.2  1302.5 ± 788.1 
IHC (positive/negative)  2/9  1/2 
Clinical Activity Index 
  
 
before GMAA 9.9 ± 0.9 11.5 ± 1.7 
 
after GMAA 1.9 ± 0.3 8.0 ± 1.7 
Clinical remission by GMAA  11 (100) 0 
Mayo Endoscopic Score 
  
 
before GMAA 2.3 ± 0.2 2.3 ± 0.3 
 
after GMAA 0.5 ± 0.2 2.8 ± 0.3 
Mucosal healing by GMAA  10 (90.9) 0 
Number of patients is shown for sex, disease location, previous treatment, IHC, clinical remission by GMAA 
and mucosal healing by GMAA. Data are presented as mean ± SE for age, disease duration, dose of 5-ASA 
and AZA/6-MP, CMV-DNA, Clinical Activity Index before and after GMAA and Mayo Endoscopic Score 
before and after GMAA.  5-ASA, 5-aminosalicylate; AZA, azathioprine; 6-MP, 6-mercaptopurine, IHC, 
immunohistochemistry. Values in parenthesis on vertical line of CMV disappearance are percentages of all 
11 patients with UC positive for CMV treated by intensive GMAA. Values in parentheses on vertical line of 
CMV appearance are percentages of all 4 patients with UC positive for CMV treated by intensive GMAA. 
Clinical remission was defined as  Clinical Activity Index ≤ 4. Mucosal healing was defined as Mayo 
Endoscopic Score of 0 or 1.  
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